CHAQ SEC filings, in plain English
Everything Chardan Healthcare Acquisition 2 Corp. has filed with the SEC that we hold — 40 filings, newest first, 1 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the financial statements are issued. As of September 30,”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Renovacor, Inc. (successor to SPAC Chardan Healthcare Acquisition 2 Corp.) and Rocket Pharmaceuticals, Inc. issued a joint proxy for special meetings on November 30, 2022, mailed on or about November 1, 2022, to approve the merger agreement signed September 19, 2022. The initial exchange ratio is 0.1676 Rocket shares for each Renovacor share, subject to adjustment, implying a value of $2.60 per Renovacor share based on a volume weighted average Rocket price of $15.51 over the 30 trading days through the measurement date. Rocket's record date is October 24, 2022. Why it matters: An implied $2.60 per Renovacor share is roughly a quarter of the $10.00 per share the Chardan Healthcare 2 trust originally held, so legacy SPAC holders who rolled into the deal instead of redeeming crystallise a loss of about 74% in this exchange. The ratio is subject to adjustment and the final value will not be known when Renovacor stockholders vote, so the $2.60 figure is indicative rather than fixed. Holders receive Rocket stock rather than cash, converting a failed gene therapy position into exposure to a larger developer.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.